Management of health risk related to use of engineered nanomaterials. An analogy with biosafety by Prodanov Dimiter
© Bulgarian Society for Cell Biology
ISSN 1314-1929 (online)
MANAGEMENT OF HEALTH RISK RELATED TO USE OF ENGINEERED
NANOMATERIALS. AN ANALOGY WITH BIOSAFETY
Dimiter Prodanov
Environment, Health and Safety, Imec, Belgium
ABSTRACT
Safety of nanomaterials is a new scientific field, which draws increasing attention in literature.  Among the challenges the 
field is facing are the insufficient amount and quality of nanotoxicological data and the ambiguity in the metrics 
describing the exposure. This results in substantial difficulties in the actual quantification of risk in terms of dose-response 
relationships and exposure limits, which are a cornerstones of chemical risk assessment. While there is no golden standard 
for risk assessment and management several pragmatic systems have come into being. All of these employ some form of 
categorization and grouping of (nano)materials into hazard groups. The present review aims to draw analogies between the 
nascent field of nanosafety and the well established field of biosafety, where the risk is also difficult to quantify. Biomed Rev 
2017; 28:104-109.
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NANOMATERIALS
The nanomaterials are broadly defined as those materials 
that have a certain percentage of particles at the nanoscale 
between 1 and 100 nm (see below). Particles of this size can 
get deposited in the lungs, pass easily through alveoli or even 
disperse in the body. While the size cut-off is somehow arbi-
trary it nevertheless conveys the important fact that properties 
of the features at nanoscale (i.e. nanoforms) can substantially 
differ from the properties of “macro” materials in bulk. Such 
desirable characteristics can include increased strength of the 
material, its chemical reactivity or altered electrical proper-
ties. These features offer possibilities for new applications in 
a broad range of sectors; for example in medicine (e.g. detec-
tion of genetic sequences using DNA-tagged gold nanoparti-
cles); environment (e.g. waste-water treatment with carbon 
nanotube filters); or energy production (e.g. solar cells using 
silicon nanocrystals). At the same time, the use of manufac-
tured nanomaterials in a number of commercial applications 
raises questions regarding potential unintended risks for the 
workers, consumers and the environment.
Top-down and bottom-up approaches to nanotechnology 
Nano-enabled technologies have been with mankind for cen-
turies, if not millennia. What, however, makes modern nano-
technology unique is the aspect of deliberate exploitation of 
the nanoscale: Nanotechnology by difinition uses 
intentionally desirable properties of materials at the 
nanoscale to deliver economi-cally beneficial effects. From 
technological perspective there are two complementary 
approaches: top-down and bottom-up processing. While the 
bottom-up approach can be broadly identified as particle 
synthesis, or self-assembly; top-down approach can be 
thought of growth or deposition on surfaces. An example of 
the latter is micro or nano-electronics indus-try.  
Nanomaterial manufacturers typically  employ bottom-up 
approaches, while end-user industries incorporate engi-
neered nanomaterials on macroscopic objects, e.g.  products 
like computer chips, tires, sportswear. From industrial end-
user perspective the innovation cycle leads to new materials 
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and nanoforms being introduced in manu-
facturing. Typically, the product develop-
ment runs ahead of establishing metrics 
for the occupational and environmental 
hazards of these materials. Examples in-
clude nanoelctronics,   automotive, cos-
metics and painting industries. 
INTERNATIONAL EFFORTS
AND EU INITIATIVES
IN NANOSAFETY RESEARCH
Traditional chemical risk assessment 
tools are based on a quantitative dose-re-
sponse relationship, which is augmented 
by setting a threshold defining  the no-
effect levels, or occupational exposure 
limit (OEL). This type of risk assessment 
is applicable in cases when sufficient tox-
icological and occupational exposure data 
are available. Understanding properties 
of engineered  nano-materials and how 
they affect living systems, such as the hu-
man body, draws substantial attention in 
recent scientific literature  (Fig. 1). While 
sions is in the size range 1 nm - 100 nm.
In specific cases and where warranted by concerns for 
the environment, health, safety or competitiveness the num-
ber size distribution threshold of 50 % may be replaced by a 
threshold between 1 and 50 %. By derogation from the above, 
fullerenes, graphene flakes and single wall carbon nanotubes 
with one or more external dimensions below 1 nm should be 
considered as nanomaterials. 
On the other hand, ISO defines a nano-object simply as 
“material with one, two or three external dimensions in the 
nanoscale”, that is between 1 and 100 nm. To address so-
outlined scienfic and regulatory challenges international 
bodies, such as the European Union and the Organisation 
for Economic Co-operation and Development (OECD),  
have orchestrated substantial efforts. For example, the EU 
NanoSafety Cluster (www.nanosafetycluster.eu) is a 
network of projects in the funding programs FP6 (2002–
2006), FP7 (2007–2013), and  H2020 (2014–2020) 
framework programmes, intended at harmonizing the 
European Commission-funded in nanosafety research. Over 
that time, more than 50 projects have been associated with 
the NanoSafety Cluster. 
    Challenges in the risk assessment approach can be traced 
to the assumption that the hazard and the risk can be quan-
Figure 1. Number of article per year according related to safety of nanotechnolo-
gies according to key word combinations. Records were collected come from 
the PubMed database using the trend tool from (5).
the predominant number of studies are focused on the materi-
als, relatively smaller amounts discuss more comprehensive 
safety questions.
It becomes increasingly clear that harmful properties of 
nanoforms sometimes do not correlate with the toxicological 
profile of the bulk materials. There are several reasons for 
that, notably the change of scale leads to a relative increase of 
the fraction of particles which are on the surface of the nanoo-
bject. The curvature and charge density also increase with the 
decrease of size. One of the challenges in nano-toxicology is 
therefore, the identification of the best metric for toxicologi-
cal assessment (11). While traditional metrics are based on 
mass concentration, the majority of authors at present favor 
particle number based metrics. 
A related challenge is how a nanomaterial can be de-
fined as there are several different definitions internationally. 
According to the current recommendation by the European 
Commission a nanomaterial means:
A natural, incidental or manufactured material contain-
ing particles, in an unbound state or as an aggregate or as 
an agglomerate and where, for 50 % or more of the particles 
in the number size distribution, one or more external dimen-
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It is currently believed that conventional risk assessment 
tools have limited applicability to nanomaterials (3, 4, 6, 8, 11). 
This is due to several factors, mainly insuffient hazard 
characterization data and the lack of standards of reference 
methods and nanomaterials. A summary can be given as follows:
1. Insuffient h azard characterization l eads t o limited
availability of data on physico-chemical properties, (eco)tox-
Figure 2. Holistic view of risk management as implementation of the Safe-by-design principle.
tified. From t he  biosafety practice, we know that this 
may not (ever) be the case.  A holistic view of the nano-
hazard and the related process risk is crucial for successful 
integration of nanosafety aspects into the overall risk 
management method-ology. Material properties, health 
effects, potential of release and occupational exposure are 
principal aspects for success-ful risk mitigation (Fig. 2). 
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While there is no golden standard for risk assessment and 
management several pragmatic systems have come into be-
ing. So identified gaps in understanding promote the view 
that the most promising approaches for management of na-
no-related risk are the risk and control- banding tools (Table 
1), which are akin to the biohazard grouping. Efforts in 
the direction of grouping of nanomaterials and read-across 
missing properties of nanoforms are encouraged by the 
stakeholders, such as the nanotechnology industry, national 
regulators and international bodies, like OECD. There is a 
recent international standard dealing with nanosafety in oc-
cupational settings: ISO Technical Standard ISO/TS 12901-
2:2014 “Nanotechnologies - Occupational risk management 
applied to engineered nanomaterials”. The standard is fo-
cused on intentionally produced nano-objects, such as nano-
particles, nanopowders, nanotubes, nanowires, as well as of 
aggregates and agglomerates and is focused on the manage-
ment of the inhalation hazard.  The standard defines 5 na-
nohazard groups which combine with four exposure bands 
(Table 2). This is constrained by 5 control bands, which 
identify measures to be implemented in order to reduce the 
risk for the personnel.
Tool Type Result Interpretation Reference
ISO standard Decision tree Categorical Preventive control ISO 2014
Imec Survey Categorical Occupational risk assessment Van Hoornick et al, 2016
CB Nanotool Score Semi-quantitative Preventive control Paik, Park, 2009
ANSES Decision tree Categorical Preventive control ANSES, 2010
Nano Stoffenmanager Decision tree + Score Categorical Risk prioritization Duuren-Stuurman et al, 2012
Table 1. Risk and control banding tools
ISO Hazard class Definition Examples
Category A No significant risk to health Non-toxic soluble nanoparticles
Category B Slight Hazard – Slightly toxic -
Category C Moderate Hazard -
Category D Serious hazard -
Category E Severe hazard Carciongenic insoluble nanoparticles, 
insoluble fibers, such as carbon nanotubes
icological properties and the environmental fate information, 
all of which are pre-requisites for comprehensive risk assess-
ment. This insufficiency stemmed from the fact that nanoma-
terials of the same type can exhibit different properties due 
to the difference in synthesis method, therefore, the results 
obtained from one study might not generalize, thus rendering 
their use limitted (3, 4, 6).
2. Poorly designed experimental protocols can lead to
false positive or negative toxicological results because nano-
particles have been shown to directly interfere with the bio-
logical/toxicological assays used.  Recent publications  have 
demanded for a uniform standard operating procedures so 
that results obtained from different studies can be compara-
ble and that a more concrete conclusion can be drawn (6, 8).
3. Additionally, due to the lack of data, occupational ex-
posure limits (OELs) for most types of nanoparticles are un-
known (NIOSH 2009; 11). The OELs for bulk parent materi-
als can significantly differ from their nano counterparts due to 
the unique physico-chemical properties exhibted in the nano 
form and therefore, the two OELs are not interchangeable.
4. The best metric (by mass, concentration or number)
for nanoparticles exposure characterization is still debatable.
Table 2. Hazard grouping according to ISO/TS 12901
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WHAT CAN WE LEARN FROM BIOSAFETY?
In biosafety practice,  there are 4 biohazard groups and 4 
major biocontainment levels (Table 2). Biosafety levels are 
based on a composition of facility design features, contain-
ment infrastructure, specialized equipment, work practices 
and operational procedures required for working with agents 
from the four risk groups (13). The emphasis is on the clas-
sification of biological agents based on the similarity of their 
action on a healthy human being. That is, the risk is 
measured in a relative way! This pragmatic classification 
provides the backbone for management of  biorisk in 
laboratory setting for more than 20 years. 
The current expert opinion identifies grouping criteria as 
priority in nanosafety research (11).  In contrast to biosafety 
practice, in nanotechnology, each step of a process where na-
nomaterials are used or produced is assigned a particular risk 
level, which in turn determines the appropriate risk control 
measures. In my view, there are a number of synergies be-
tween both fields that can be exploited for cross-fertilization 
of the efforts. This is an open field of research, which may 
lead us out of the maze of conflicting nanotoxicology reports.
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